1. Novo Nordisk's Q2 earnings fell short of expectations with a cautious growth outlook, but the market reaction was overly pessimistic; 2. Wegovy, its blockbuster weight-loss drug, continues to drive strong revenue despite competition and counterfeit products; 3. Eli Lilly's underwhelming weight-loss drug results and Novo's CEO transition improve sentiment, while its 12.2X forward P/E valuation presents a contrarian opportunity amid rising obesity trends.
Related Articles
- JP Morgan: Q3 Earnings, The Stock Is Inflated - Why I'm Still Long10 months ago
- Why I'm Selling Nvidia Ahead Of Q2 Earnings12 months ago
- DiDi Global: Slower Growth But More Profitable12 months ago
- Palo Alto Networks Q4 Earnings: Paying A Premium For Yesterday's Security (Upgrade)12 months ago
- Ranpak Holdings: A Downgrade Is In Order On Valuationabout 1 year ago
- Amazon's Q2 Will Likely Surprise Youabout 1 year ago
- Verizon Communications Remains A Compelling Value Playabout 1 month ago
- S&P 500 Earnings: Nothing Much This Week, But Don't Ignore Non-Correlatedabout 1 month ago
- Starbucks: Strategy Might Take A While To See Its Resultsabout 2 months ago
- AppLovin: Ushering In A New Reign Of Advertisingabout 2 months ago